Jeil Pharmaceutical’s new diabetes type I drug development selected as MOHW’s project

Published: 2017-09-26 16:42:29

Updated: 2017-09-26 16:42:29

‘JP -2266,’ a new oral diabetes type I drug being developed by Jeil Pharmaceutical(CEO/President Seok-Jae Sung), was selected as the Ministry of Health and Welfare’s high-tech medical technology development(new drug development support) project.

As being selected as a new supported project, ‘JP-2266’ will be completed in a non-clinical GLP toxicity study for 2 years and is expected to be devel...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.